Zhangzhou Pientzehuang Pharmaceutical (600436.SH): Net profit in 2024 was 2.974 billion yuan, a year-on-year increase of 6.32%.

Zhangzhou Pientzehuang Pharmaceutical (600436.SH) released its 2024 annual performance report, reporting a total operating income of 10.769 billion yuan during the reporting period, a year-on-year increase of 7.06%; a net profit attributable to shareholders of the listed company of 2.974 billion yuan, a year-on-year increase of 6.32%; a net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses of 3.043 billion yuan, a year-on-year increase of 6.62%; and a basic earnings per share of 4.93 yuan. The main reasons for the performance growth are as follows: the company strengthened market planning and expanded sales channels, leading to an increase in sales of core products Zhangzhou Pientzehuang Pharmaceutical series and Zhangzhou Pientzehuang Pharmaceutical branded Angong Niuhuang Pills. Due to factors such as changes in medical insurance policies and a shrinking consumer market, the revenue of the pharmaceutical distribution industry decreased year-on-year, but the company's total operating income increased by 13.29% after deducting the pharmaceutical distribution industry.